Eric Becker is the Co-Founder and Co-Chairman of Cresset, an award-winning multi-family office with over $40+ billion assets under management and has a history of nurturing new companies, sharing his extensive experience and providing mentorship and guidance to founders and entrepreneurs.

With almost four decades of clinical and scientific research focused on the diagnosis, treatment, and cell biology of reflux, Dr. Koufman personally coined the terms laryngopharyngeal reflux, silent reflux, airway reflux, and the newest term, respiratory reflux.

Prakash Gowd brings over 25 years of experience in executive management, strategic business analysis, corporate development, financing, and capital markets focused on the healthcare and biopharma sectors.

Dr. Carroll's research focuses on the symptom overlap of glottic insufficiency and laryngopharyngeal reflux disease. He has a special interest in non-acidic reflux and chronic cough. His research focuses on the symptom overlap of glottic insufficiency and laryngopharyngeal reflux disease.

Jerome is a 33 yo Otolaryngologist (M.D., Ph.D., M.Sc.) from Foch Hospital (Paris) and CHU de Bruxelles (Brussels). He is Professor of Otolaryngology, Anatomy & Physiology at University of Mons, Belgium.

Dr. Brian Jahns is an accomplished senior executive whose extensive experience spans pharma and biotech, mature organisations, and start-ups. His expertise spans operational and commercial excellence, formulation of strategy, licensing, partnering, and scientific affairs.

Dr. Hastedt has over 35 years of experience in pharmaceutical product development, managing and leading the development of small molecules, peptides, and proteins. Supported successful US and EU regulatory approvals. Her experience includes leading physicochemical characterization and CMC development activities spanning early drug product development and launch.

Dana’s industry experience includes the development of regulatory strategies throughout various phases of clinical investigation, extensive interactions with regulatory authorities, and submissions to health agencies in the United States, Canada and Europe. In addition, she has implemented and maintained quality systems, prepared for and participated in agency audits, and developed internal training programs.

Professor Scarpignato is an internationally acclaimed clinical pharmacologist and gastroenterologist with significant experience in the successful development of drugs for digestive diseases. He is a scientific consultant to several National and International Pharmaceutical Companies working in the GI field.